secwatch.observer — SEC 8-K summary
======================================

Issuer:     Xencor Inc (XNCR)
CIK:        0001326732
Form:       8-K
Filed at:   2023-09-19T23:59:59+00:00
Accession:  0001326732-23-000028
Event type: leadership
Sentiment:  neutral
Materiality: 0.35
Item codes: 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Xencor adds Barbara Klencke, M.D., to board; board expands to eight members
---------------------------------------------------------------------------

- Board increased from 7 to 8 members; Dr. Klencke appointed effective Sept 15, 2023.
- Dr. Klencke receives initial stock option with Black-Scholes value of $550,000, vesting over 3 years.
- Annual cash retainer of $50,000 for board service; standard indemnification agreement.
- Dr. Klencke previously CMO and CDO at Sierra Oncology; led Ojjaara approval for myelofibrosis.
- Also serves on boards of eFFECTOR Therapeutics, Immune-Onc Therapeutics, and TScan Therapeutics.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1326732/000132673223000028/0001326732-23-000028-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1326732/000132673223000028/xncr-20230915.htm
  HTML page:      https://secwatch.observer/filing/0001326732-23-000028

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer